Project Grant R01CA289009
Award Date
12/4/24
Completion Date
11/30/29
Dollars Obligated
$702K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, is focused on uncovering the core mechanisms driving lineage plasticity in EGFR-mutant lung adenocarcinoma (LUAD). The $631,156 award will fund a 5-year research project conducted by the Icahn School of Medicine at Mount Sinai to systematically investigate the genetic, transcriptomic, and epigenomic changes underlying the transformation of LUAD to the more...
This $3,787,956 federal Project Grant award, issued by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), is funding a multi-year research program at New York University School of Medicine to investigate and target replication stress in small cell lung cancer (SCLC). The program aims to understand how the SLFN11 gene and replication stress response pathways regulate chemosensitivity in SCLC subtypes, and to develop strategies to combat acquired...
This $642,429 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to understand the mechanisms driving cross-resistance in small cell lung cancer (SCLC). The primary grantee, the University of Texas Southwestern Medical Center, is developing and analyzing a panel of 72 patient-derived SCLC xenograft models to investigate how genetic alterations, particularly MYC amplifications on extrachromosomal DNA, contribute to broad drug...
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410 to New York University School of Medicine to conduct research aimed at understanding the molecular mechanisms underlying the adeno-to-squamous transition observed in non-small cell lung cancer patients treated with KRAS inhibitors. The key objectives are to: Identify chromatin regulators that drive the adeno-to-squamous transition through a perturbation screen, and then...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The $256,487 grant, effective August 13, 2024, supports a 5-year research project to develop multimodal predictive models for non-small cell lung cancer (NSCLC) using real-world data sources such as circulating tumor DNA sequencing, tumor genomics, and clinician notes. The goal is to improve risk stratification and clinical...
This $216,972 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Temple University aimed at understanding and targeting vulnerabilities in small cell lung cancer (SCLC). The key objectives are to: Determine the mechanistic underpinnings of increased replication stress in SCLC, including the role of low LMNA (a nuclear structural protein) and R-loops (RNA-DNA hybrids). This research will inform new therapeutic approaches targeting...
This Project Grant award of $191,675 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports innovative research by the University of Texas Southwestern Medical Center to investigate the role of Jumonji lysine demethylases as potential therapeutic targets for small cell lung cancer (SCLC). The key products or services to be delivered under this grant include: 1) Evaluating the efficacy of Jumonji inhibitors as first-line therapy for SCLC, including in SCLC resistant...
The National Cancer Institute (NCI) awarded the Icahn School of Medicine at Mount Sinai a $237,023 Project Grant under the Cancer Biology Research (CFDA 93.396) program to develop a scalable and cost-effective single-cell multi-omic profiling method (SHARE-ME-SEQ). This method will jointly capture gene expression, chromatin accessibility, and DNA methylation at the single-cell level, with the goal of identifying and targeting methylation-driven pathways in acute myeloid leukemia (AML). The...
The National Cancer Institute (NCI) awarded a $680,334 Project Grant under the Cancer Biology Research (CFDA 93.396) federal grant program to the Icahn School of Medicine at Mount Sinai (ISMMS). The 5-year grant, which began on March 1, 2025, aims to elucidate the specific molecular mechanisms and cellular players driving age-associated pro-tumoral myelopoiesis. The research will involve high-dimensional profiling of tumors from an early-stage lung cancer patient cohort, multi-omics...